Company: TAK
Filing Date: 2025-01-30
Form Type: 6-K
Source: 0001395064-25-000002
Chunk: 27

Company: TAKEDA PHARMACEUTICAL CO LTD
Filing Date: 2025-01-30
Form: 6-K
Chunk 27
---
 the Nine-month

Period Ended December 31, 2024 (Consolidated)

(6) Notes to Condensed Interim Consolidated Financial Statements

(Significant Uncertainty Regarding Going Concern Assumption)

Not applicable.

(Material Accounting Policies)

Material accounting policies adopted for the condensed interim consolidated financial statements are the same as those adopted for the consolidated financial statements as of and for the fiscal year ended March 31, 2024.

Takeda calculated income tax expenses for the nine-month period ended December 31, 2024, based on the estimated average annual effective tax rate.

(Operating Segment Information)

Takeda comprises a single operating segment and is engaged in the research, development, manufacturing, marketing and out-licensing of pharmaceutical products. This is consistent with how the financial information is viewed in allocating resources, measuring performance, and forecasting future periods by the CEO who is Takeda’s Chief Operating Decision Maker.

(Significant Changes in Equity Attributable to Owners of the Company)

Not applicable.

(Significant Subsequent Events)

On January 30, 2025, Takeda resolved to engage in the acquisition of its own shares at the Board of Directors Meeting pursuant to the provision of its Articles of Incorporation in accordance with Article 459, paragraph 1 of the Companies Act of Japan.

1. Reason for acquisition of its own shares

To enhance capital efficiency and improve shareholder returns

2. Details of acquisition

Class of shares to be acquired: Shares of common stock

Number of shares to be acquired: Up to 28.5 million shares

(equivalent to 1.80% of the total number of shares

outstanding excluding treasury shares)

Total amount of shares to be acquired: Up to JPY 100 billion

Schedule of acquisition: From February 17, 2025 to May 31, 2025

Method of acquisition: Open-market repurchase through a trust bank

<div align='center'>23</div>